Rachel Gaul

Rachel Gaul

Auto-generated profile, based on publicly available information

Rachel Gaul

School of Pharmacy and Tissue Engineering Research Group, Royal College of Surgeons in Ireland, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Molecular Therapy
Verified
Journal Article
Open access
CSChiara De Santi
Chiara De Santi
Elena Fernández  FernándezElena Fernández Fernández
Elena Fernández Fernández
RGRachel Gaul
Rachel Gaul
SVSebastian Vencken
Sebastian Vencken
AGArlene Glasgow
Arlene Glasgow
CGCatherine M. Greene
Catherine M. Greene
MicroRNAs that are overexpressed in cystic fibrosis (CF) bronchial epithelial cells (BEC) negatively regulate CFTR and nullify the beneficial effects of CFTR modulators. We hypothesized that it is possible to reverse microRNA-mediated inhibition of CFTR using CFTR-specific target site blockers (TSBs) and to develop a drug-device combination inhalation therapy for CF. Lead microRNA expression was quantified in a series of human CF and non-CF samples and in vitro models. A panel of CFTR 3' untranslated region (UTR)-specific locked nucleic acid antisense oligonucleotide TSBs was assessed for their ability to increase CFTR expression. Their effects on CFTR activity alone or in combination with CFTR modulators were measured in CF BEC models. TSB encapsulation in poly-lactic-co-glycolic acid (PLGA) nanoparticles was assessed as a proof of principle of delivery into CF BECs. TSBs targeting the CFTR 3' UTR 298-305:miR-145-5p or 166-173:miR-223-3p sites increased CFTR expression and anion channel activity and enhanced the effects of ivacaftor/lumacaftor or ivacaftor/tezacaftor in CF BECs. Biocompatible PLGA-TSB nanoparticles promoted CFTR expression in primary BECs and retained desirable biophysical characteristics following nebulization. Alone or in combination with CFTR modulators, aerosolized CFTR-targeting TSBs encapsulated in PLGA nanoparticles could represent a promising drug-device combination therapy for the treatment for CFTR dysfunction in the lung.

1 January 2018
Verified
Book Chapter
Closed access
RGRachel Gaul
Rachel Gaul
JRJoanne Ramsey
Joanne Ramsey
AHAndreas Heise
Andreas Heise
SCSally-Ann Cryan
Sally-Ann Cryan
CGCatherine M. Greene
Catherine M. Greene